Psoriasiform Dermatitis: From Pathogenesis to New Therapeutic Opportunities
Abstract
1. Introduction
2. Methods
3. Pathogenesis
4. Clinical Features
5. Diagnosis
6. Histopathology
7. Advanced Imaging
8. Treatment Approaches
8.1. Topical Therapies
8.2. Experimental and Non-Conventional Agents
8.3. JAK Inhibitors
8.4. PDE4 Inhibitors (Apremilast)
8.5. Anti-IL-17
8.6. Anti-IL-23
8.7. Anti-IL-4/IL-13
9. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Wick, M.R. Psoriasiform dermatitides: A brief review. Semin. Diagn. Pathol. 2017, 34, 220–225. [Google Scholar] [CrossRef] [PubMed]
- Ali, K.; Wu, L.; Qiu, Y.; Li, M. Case report: Clinical and histopathological characteristics of psoriasiform erythema and de novo IL-17A cytokines expression on lesioned skin in atopic dermatitis children treated with dupilumab. Front. Med. 2022, 9, 932766. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Liu, T.; Li, S.; Ying, S.; Tang, S.; Ding, Y.; Li, Y.; Qiao, J.; Fang, H. The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside. Front. Immunol. 2020, 11, 594735. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Zhu, H.; Jiang, J.; Yang, M.; Zhao, M.; He, Z.; Tang, C.; Song, C.; Akbar, A.N.; Reddy, V.; Pan, W.; et al. Topical application of a BCL-2 inhibitor ameliorates imiquimod-induced psoriasiform dermatitis by eliminating senescent cells. J. Dermatol. Sci. 2024, 115, 54–63. [Google Scholar] [CrossRef] [PubMed]
- George, L.A.; Gadani, A.; Cross, R.K.; Jambaulikar, G.; Ghazi, L.J. Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease. Dig. Dis. Sci. 2015, 60, 3424–3430. [Google Scholar] [CrossRef] [PubMed]
- Gambardella, A.; Calabrese, G.; Di Brizzi, E.V.; Alfano, R.; Argenziano, G. A case of Atopic dermatitis and Hidradenitis Suppurativa successfully treated with Dupilumab. J. Eur. Acad. Dermatol. Venereol. 2020, 34, e284–e286. [Google Scholar] [CrossRef] [PubMed]
- Ferrucci, S.; Tavecchio, S.; Maronese, C.A.; Balato, A.; Di Brizzi, E.V.; Ortoncelli, M.; Ribero, S.; Girolomoni, G.; Maurelli, M.; Fortina, A.B.; et al. Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: A real-world multicentre Italian study of 2576 patients. Clin. Exp. Dermatol. 2024, 49, 1561–1572. [Google Scholar] [CrossRef] [PubMed]
- Napolitano, M.; Foggia, L.; Patruno, C.; Gallo, L.; Tommasino, N.; Cecere, D.; Megna, M. Efficacy of Janus kinase inhibitors in the treatment of psoriasiform atopic dermatitis. Clin. Exp. Dermatol. 2024, 49, 1232–1234. [Google Scholar] [CrossRef] [PubMed]
- Salvi, I.; Parodi, A.; Cozzani, E.; Burlando, M. Case report: Psoriasiform eczema with immune-mediated comorbidities treated with upadacitinib. Front. Immunol. 2024, 15, 1432233. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Tortola, L.; Rosenwald, E.; Abel, B.; Blumberg, H.; Schäfer, M.; Coyle, A.J.; Renauld, J.-C.; Werner, S.; Kisielow, J.; Kopf, M. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J. Clin. Investig. 2012, 122, 3965–3976. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Huang, Y.; Wang, Y.; Zhen, Y.; Liu, W.; Wang, Y.; Wang, R.; Wang, N.; Huang, S.; Yan, J.; Sun, Q. LPCAT1 Facilitates Keratinocyte Hyperproliferation and Skin Inflammation in Psoriasis by Regulating GLUT3. J. Investig. Dermatol. 2024, 144, 1479–1490.e14. [Google Scholar] [CrossRef] [PubMed]
- Blanchard, G.; Bisig, B.; de Leval, L.; Hohl, D.; Guenova, E. Cytokine-pathway blockers worsen mycosis fungoides masquerading as psoriasis. JAAD Case Rep. 2024, 48, 98–102. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Liu, J.; Qiu, C.; Zhou, Z.; Li, J.; Zhen, Y.; Wang, R.; Zhuang, Y.; Zhang, F. Pentraxin 3 exacerbates psoriasiform dermatitis through regulation of macrophage polarization. Int. Immunopharmacol. 2024, 130, 111805. [Google Scholar] [CrossRef] [PubMed]
- Popa, L.G.; Giurcaneanu, C.; Portelli, M.G.; Mihai, M.M.; Beiu, C.; Orzan, O.A.; Ion, A.; Anghel, T.H. Perspectives on Psoriasiform Adverse Events from Immune Checkpoint Inhibitors: Lessons Learned from Our Practice. Medicina 2024, 60, 373. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Bezdek, S.; Leng, L.; Busch, H.; Mousavi, S.; Rades, D.; Dahlke, M.; Zillikens, D.; Bucala, R.; Sadik, C.D. Macrophage Migration Inhibitory Factor (MIF) Drives Murine Psoriasiform Dermatitis. Front. Immunol. 2018, 9, 2262. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Billi, A.C.; Ludwig, J.E.; Fritz, Y.; Rozic, R.; Swindell, W.R.; Tsoi, L.C.; Gruzska, D.; Abdollahi-Roodsaz, S.; Xing, X.; Diaconu, D.; et al. KLK6 expression in skin induces PAR1-mediated psoriasiform dermatitis and inflammatory joint disease. J. Clin. Investig. 2020, 130, 3151–3157. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Diaz-Perez, J.A.; Killeen, M.E.; Yang, Y.; Carey, C.D.; Falo, L.D.; Mathers, A.R. Extracellular ATP and IL-23 Form a Local Inflammatory Circuit Leading to the Development of a Neutrophil-Dependent Psoriasiform Dermatitis. J. Investig. Dermatol. 2018, 138, 2595–2605. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Stingeni, L.; Bianchi, L.; Antonelli, E.; Caroppo, E.S.; Ferrucci, S.M.; Gurioli, C.; Ortoncelli, M.; Fabbrocini, G.; Nettis, E.; Schena, D.; et al. A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis. J. Eur. Acad. Dermatol. Venereol. 2023, 37, e384–e388. [Google Scholar] [CrossRef] [PubMed]
- Parker, J.J.; Sugarman, J.L.; Silverberg, N.B.; Gonzalez, M.E.; Ramien, M.L.; Teng, J.M.C.; Paller, A.S. Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children. Pediatr. Dermatol. 2021, 38, 1500–1505. [Google Scholar] [CrossRef] [PubMed]
- Patruno, C.; Fabbrocini, G.; De Lucia, M.; Picone, V.; Genco, L.; Napolitano, M. Psoriasiform dermatitis induced by dupilumab successfully treated with upadacitinib. Dermatol. Ther. 2022, 35, e15788. [Google Scholar] [CrossRef] [PubMed]
- Bieber, K.; Bezdek, S.; Gupta, Y.; Vorobyev, A.; Sezin, T.; Gross, N.; Prüssmann, J.; Sayegh, J.; Becker, M.; Mousavi, S.; et al. Forward genetics and functional analysis highlight Itga11 as a modulator of murine psoriasiform dermatitis. J. Pathol. 2023, 261, 184–197. [Google Scholar] [CrossRef] [PubMed]
- Tian, S.; Chen, S.; Feng, Y.; Li, Y. The Interactions of Small Proline-Rich Proteins with Late Cornified Envelope Proteins are Involved in the Pathogenesis of Psoriasis. Clin. Cosmet. Investig. Dermatol. 2021, 14, 1355–1365. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Mehta, S.; Singal, A.; Singh, N.; Bhattacharya, S.N. A study of clinicohistopathological correlation in patients of psoriasis and psoriasiform dermatitis. Indian. J. Dermatol. Venereol. Leprol. 2009, 75, 100. [Google Scholar] [CrossRef] [PubMed]
- Di Brizzi, E.V.; Buononato, D.; Benvenuto, P.; Argenziano, G.; De Pasquale, R.; Fiorella, C.S.; Gioffrè, C.; Musumeci, M.L.; Palazzo, G.; Zichichi, L.; et al. Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis. Dermatol. Pract. Concept. 2023, 13, e2023215. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Gargiulo, L.; Ibba, L.; Ingurgio, R.C.; Malagoli, P.; Amoruso, F.; Balato, A.; Bardazzi, F.; Brianti, P.; Brunasso, G.; Burlando, M.; et al. Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: A 16-week multicenter retrospective study-IL PSO (Italian landscape psoriasis). J. Dermatol. Treat. 2024, 35, 2350760. [Google Scholar] [CrossRef] [PubMed]
- Barr, R.J.; Young, E.M., Jr. Psoriasiform and related papulosquamous disorders. J. Cutan. Pathol. 1985, 12, 412–425. [Google Scholar] [CrossRef] [PubMed]
- Patrizi, A.; Bardazzi, F.; Neri, I.; Fanti, P.A. Psoriasiform acral dermatitis: A peculiar clinical presentation of psoriasis in children. Pediatr. Dermatol. 1999, 16, 439–443. [Google Scholar] [CrossRef] [PubMed]
- Tosti, A.; Fanti, P.A.; Morelli, R.; Bardazzi, F. Psoriasiform acral dermatitis. Report of three cases. Acta Derm. Venereol. 1992, 72, 206–207. [Google Scholar] [CrossRef] [PubMed]
- Lallas, A.; Zalaudek, I.; Argenziano, G.; Longo, C.; Moscarella, E.; Di Lernia, V.; Al Jalbout, S.; Apalla, Z. Dermoscopy in general dermatology. Dermatol. Clin. 2013, 31, 679–694. [Google Scholar] [CrossRef] [PubMed]
- Di Brizzi, E.V.; Moscarella, E.; Piana, S.; Longo, C.; Franco, R.; Alfano, R.; Argenziano, G. Clinical and dermoscopic features of pleomorphic dermal sarcoma. Australas. J. Dermatol. 2019, 60, e153–e154. [Google Scholar] [CrossRef] [PubMed]
- Corneli, P.; Moscarella, E.; Di Brizzi, E.V.; Ronchi, A.; Zalaudek, I.; Alfano, R.; Argenziano, G. Pigmented Squamous Cell Carcinoma: Is the Reported Prevalence Real? Dermatol. Pract. Concept. 2019, 9, 150–151. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Sutarjono, B.; Lebovitch, H. Psoriasiform spongiotic dermatitis. BMJ Case Rep. 2019, 12, e228690. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Scharf, C.; Di Brizzi, E.V.; Licata, G.; Piccolo, V.; Argenziano, G.; Moscarella, E. Reflectance confocal microscopy in paediatric patients: Applications and limits. Exp. Dermatol. 2023, 32, 210–213. [Google Scholar] [CrossRef] [PubMed]
- Benvenuto, P.; Tancredi, V.; Ronchi, A.; Scharf, C.; Fulgione, E.; Moscarella, E. In Vivo Characterization of the Inflammatory Infiltrate in Discoid Lupus Erythematosus (DLE) by Line-Field Confocal Optical Coherence Tomography (LC-OCT). Dermatol. Pract. Concept. 2025, 15, 5089. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Mao, J.; Du, N.; Jia, Y.; Mao, Q.; Yang, J.; Zhang, Y.; Li, Y.; Cao, L.; Min, W. Case report: Treatment of psoriasiform dermatitis in patients with malignancy. Front. Med. 2024, 11, 1363405. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Kurihara, K.; Fujiyama, T.; Tokura, Y.; Honda, T. Two cases of psoriasiform dermatitis arising during dupilumab therapy and successfully treated with delgocitinib ointment. Eur. J. Dermatol. 2021, 31, 658–660. [Google Scholar] [CrossRef] [PubMed]
- Jiang, Y.; Lu, S.; Lai, Y.; Wang, L. Topical histone deacetylase 1 inhibitor Entinostat ameliorates psoriasiform dermatitis through suppression of IL-17A response. J. Dermatol. Sci. 2023, 110, 89–98. [Google Scholar] [CrossRef] [PubMed]
- Wang, P.; Killeen, M.E.; Sumpter, T.L.; Ferris, L.K.; Falo, L.D.; Freeman, B.A.; Schopfer, F.J.; Mathers, A.R. Electrophilic nitro-fatty acids suppress psoriasiform dermatitis: STAT3 inhibition as a contributory mechanism. Redox Biol. 2021, 43, 101987. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Okura, I.; Kamata, M.; Asano, Y.; Mitsui, A.; Shimizu, T.; Sato, S.; Tada, Y. Fingolimod ameliorates imiquimod-induced psoriasiform dermatitis by sequestrating interleukin-17-producing ?d T cells in secondary lymph nodes. J. Dermatol. Sci. 2021, 102, 116–125. [Google Scholar] [CrossRef] [PubMed]
- Chan, T.C.; Lee, M.-S.; Huang, W.-C.; Chang, W.-Y.; Krueger, J.G.; Tsai, T.-F. Capsaicin attenuates imiquimod-induced epidermal hyperplasia and cutaneous inflammation in a murine model of psoriasis. Biomed. Pharmacother. 2021, 141, 111950. [Google Scholar] [CrossRef] [PubMed]
- Miot, H.A.; Criado, P.R.; de Castro, C.C.S.; Ianhez, M.; Talhari, C.; Ramos, P.M. JAK-STAT pathway inhibitors in dermatology. An. Bras. Dermatol. 2023, 98, 656–677. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Tancredi, V.; Buononato, D.; Caccavale, S.; Di Brizzi, E.V.; Di Caprio, R.; Argenziano, G.; Balato, A. New Perspectives in the Management of Chronic Hand Eczema: Lessons from Pathogenesis. Int. J. Mol. Sci. 2023, 25, 362. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Samuel, C.; Cornman, H.; Kambala, A.; Kwatra, S.G. A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring. Dermatol. Ther. 2023, 13, 729–749. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Shahriari, N.; Strober, B.; Shahriari, M. Upadacitinib for the treatment of psoriasiform and spongiotic dermatitis: A multicenter case series. JAAD Case Rep. 2024, 49, 106–109. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Cirone, K.D.; Lovegrove, F.E. Dupilumab-induced psoriasis in a patient with atopic dermatitis successfully treated with Upadacitinib: A case report. SAGE Open Med. Case Rep. 2025, 13, 2050313X251317811. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Foggia, L.; Potestio, L.; Patruno, C.; di Vico, F.; Napolitano, M. Reply to: Upadacitinib for the management of overlapping psoriasis and atopic dermatitis: A case series. Int. J. Dermatol. 2025, 64, 218. [Google Scholar] [CrossRef] [PubMed]
- Zhong, L.; Luo, N.; Wang, Q.; Li, T.; Hao, P. Tofacitinib for the Treatment of Psoriasiform Dermatitis Caused by IL-17 Inhibitors: A Case Report. J. Inflamm. Res. 2023, 16, 2167–2172. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Tegtmeyer, K.; Zhao, J.; Maloney, N.J.; Atassi, G.; Beestrum, M.; Lio, P.A. Off-label studies on tofacitinib in dermatology: A review. J. Dermatol. Treat. 2021, 32, 399–409. [Google Scholar] [CrossRef] [PubMed]
- Zerilli, T.; Ocheretyaner, E. Apremilast (Otezla): A New Oral Treatment for Adults With Psoriasis and Psoriatic Arthritis. Pharm. Ther. 2015, 40, 495–500. [Google Scholar] [PubMed] [PubMed Central]
- Uchida, H.; Kamata, M.; Shimizu, T.; Egawa, S.; Ito, M.; Takeshima, R.; Mizukawa, I.; Watanabe, A.; Tada, Y. Apremilast downregulates interleukin-17 production and induces splenic regulatory B cells and regulatory T cells in imiquimod-induced psoriasiform dermatitis. J. Dermatol. Sci. 2021, 104, 55–62. [Google Scholar] [CrossRef] [PubMed]
- Orsini, D.; Megna, M.; Assorgi, C.; Balato, A.; Balestri, R.; Bernardini, N.; Bettacchi, A.; Bianchelli, T.; Bianchi, L.; Buggiani, G.; et al. Efficacy and Safety of bimekizumab in elderly patients: Real-world multicenter retrospective study-IL PSO (Italian Landscape Psoriasis). J. Dermatol. Treat. 2024, 35, 2393376. [Google Scholar] [CrossRef] [PubMed]
- Chiricozzi, A.; Coscarella, G.; Puig, L.; Vender, R.; Yeung, J.; Carrascosa, J.; Piaserico, S.; Gisondi, P.; Lynde, C.; Ferreira, P.; et al. Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort study. J. Eur. Acad. Dermatol. Venereol. 2024, 38, 2175–2185. [Google Scholar] [CrossRef] [PubMed]
- Li, M.; Yu, S.; Zhang, G.; Xie, Y.; Wei, J.C. Interleukin-17 Monoclonal Antibody Successfully Treated Psoriasiform Drug Eruption Induced by Immune Checkpoint Inhibitors: A Case Report and Review of Literature. Dermatitis 2024, 35, 410–412. [Google Scholar] [CrossRef] [PubMed]
- Li, Q.; Li, X.; Li, W.; Fan, R.; Ma, Q.; Luo, X.; Jian, H.; Chen, X.; Cao, C.; Zheng, W. Development of IL-17A inhibitor-induced atopic dermatitis-like rash in psoriasis patients: Insights into immune shift. Exp. Dermatol. 2024, 33, e14958. [Google Scholar] [CrossRef] [PubMed]
- Tan, T.L.; Taglia, L.; Yazdan, P. Drug-induced psoriasiform alopecia associated with interleukin-17 inhibitor therapy. J. Cutan. Pathol. 2021, 48, 771–774. [Google Scholar] [CrossRef] [PubMed]
- Caldarola, G.; Pirro, F.; Di Stefani, A.; Talamonti, M.; Galluzzo, M.; D’aDamio, S.; Magnano, M.; Bernardini, N.; Malagoli, P.; Bardazzi, F.; et al. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: A case series and review of the literature. Expert Opin. Biol. Ther. 2020, 20, 665–672. [Google Scholar] [CrossRef] [PubMed]
- Megna, M.; Balato, A.; Caccavale, S.; Cacciapuoti, S.; Calabrese, G.; Di Brizzi, E.V.; Di Costanzo, L.; Manzo, R.; Marino, V.; Puca, R.V.; et al. Real-Life Effectiveness and Safety of Guselkumab in Patients with Psoriasis Who Have an Inadequate Response to Ustekinumab: A 3-Year Multicenter Study. J. Clin. Med. 2024, 13, 2552. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Zhou, L.; Wang, Y.; Wan, Q.; Wu, F.; Barbon, J.; Dunstan, R.; Gauld, S.; Konrad, M.; Leys, L.; McCarthy, R.; et al. A non-clinical comparative study of IL-23 antibodies in psoriasis. MAbs 2021, 13, 1964420. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Shimizu, T.; Kamata, M.; Fukaya, S.; Hayashi, K.; Fukuyasu, A.; Tanaka, T.; Ishikawa, T.; Ohnishi, T.; Tada, Y. Anti-IL-17A and IL-23p19 antibodies but not anti-TNFα antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis. J. Dermatol. Sci. 2019, 95, 90–98. [Google Scholar] [CrossRef] [PubMed]
- Li, L.; Wu, Z.; Wu, M.; Qiu, X.; Wu, Y.; Kuang, Z.; Wang, L.; Sun, T.; Liu, Y.; Yi, S.; et al. IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis. Int. Immunopharmacol. 2020, 89 (Pt B), 107008. [Google Scholar] [CrossRef] [PubMed]
- Strecker, M.; Wlotzka, K.; Strassheimer, F.; Roller, B.; Ludmirski, G.; König, S.; Röder, J.; Opitz, C.; Alekseeva, T.; Reul, J.; et al. AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma. Oncoimmunology 2022, 11, 2127508. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Peña, A.; DeJongh, B.; Haas, M.; Harms, M. Overcoming barriers to monitoring patients taking second-generation antipsychotics. Ment. Health Clin. 2018, 8, 49–55. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
Class | Agents |
---|---|
Topical therapies | Corticosteroids, Vitamin D analogs (Calcipotriol), Retinoids, Calcineurin inhibitors (Tacrolimus, Pimecrolimus) |
JAK/STAT inhibitors | Delgocitinib (topical), Upadacitinib, Baricitinib, Abrocitinib, Tofacitinib, Gusacitinib |
IL-4/IL-13 blockade | Dupilumab (IL-4/IL-13), Tralokinumab (IL-13) |
PDE4 inhibitors | Apremilast, AFX5931 |
Retinoids (systemic) | Alitretinoin |
IL-17 inhibitors | Secukinumab, Ixekizumab, Brodalumab, Bimekizumab |
IL-23 inhibitors | Guselkumab, Risankizumab, Tildrakizumab |
Experimental agents | NO2-FAs, Fingolimod, Capsaicin |
Systemic steroids | Prednisone, Methylprednisolone |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Di Brizzi, E.V.; Caccavale, S.; Giorgio, C.M.; Argenziano, G.; Balato, A. Psoriasiform Dermatitis: From Pathogenesis to New Therapeutic Opportunities. Life 2025, 15, 1026. https://doi.org/10.3390/life15071026
Di Brizzi EV, Caccavale S, Giorgio CM, Argenziano G, Balato A. Psoriasiform Dermatitis: From Pathogenesis to New Therapeutic Opportunities. Life. 2025; 15(7):1026. https://doi.org/10.3390/life15071026
Chicago/Turabian StyleDi Brizzi, Eugenia Veronica, Stefano Caccavale, Caterina Mariarosaria Giorgio, Giuseppe Argenziano, and Anna Balato. 2025. "Psoriasiform Dermatitis: From Pathogenesis to New Therapeutic Opportunities" Life 15, no. 7: 1026. https://doi.org/10.3390/life15071026
APA StyleDi Brizzi, E. V., Caccavale, S., Giorgio, C. M., Argenziano, G., & Balato, A. (2025). Psoriasiform Dermatitis: From Pathogenesis to New Therapeutic Opportunities. Life, 15(7), 1026. https://doi.org/10.3390/life15071026